Cargando…

Lipidomics of cyclophosphamide 4‐hydroxylation in patients receiving post‐transplant cyclophosphamide

Biomarker‐guided dosing may improve the efficacy and toxicity of cyclophosphamide (CY); however, clinical studies evaluating their association with the area under the plasma concentration–time curve (AUC) of CY and its metabolites are time‐ and resource‐intensive. Therefore, we sought to identify li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navarro, Sandi L., Zheng, Zihan, Randolph, Timothy W., Nakamura, Ryotaro, Sandmaier, Brenda M., Hockenbery, David, McCune, Jeannine S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9652445/ https://www.ncbi.nlm.nih.gov/pubmed/36088654 http://dx.doi.org/10.1111/cts.13404

Ejemplares similares

Pharmacometabonomic association of cyclophosphamide 4‐hydroxylation in hematopoietic cell transplant recipients
por: McCune, Jeannine S., et al.
Publicado: (2022)

Dose-adapted post-transplant cyclophosphamide for HLA-haploidentical transplantation in Fanconi anemia
por: Thakar, Monica S., et al.
Publicado: (2017)

Is Post-Transplant Cyclophosphamide the New Methotrexate?
por: Mussetti, Alberto, et al.
Publicado: (2021)

Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients
por: Hasanah, Yesi Ihdina Fityatal, et al.
Publicado: (2021)

A Review of Cyclophosphamide-Induced Transplantation Tolerance in Mice and Its Relationship With the HLA-Haploidentical Bone Marrow Transplantation/Post-Transplantation Cyclophosphamide Platform
por: Mayumi, Hisanori
Publicado: (2021)

Post-Transplantation Cyclophosphamide: An Old Nemesis to a New Transplant Paradigm?
por: Rotz, Seth J., et al.
Publicado: (2021)

Emphysematous Cystitis in a Patient Receiving Cyclophosphamide
por: Al Zein, Said
Publicado: (2021)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Tacrolimus initial steady state level in post-transplant cyclophosphamide based GvHD prophylaxis regimens
por: Yao, Janny M., et al.
Publicado: (2022)

Post-transplant cyclophosphamide: overcoming the HLA barrier to hematopoietic stem cell transplants
por: Bacigalupo, Andrea
Publicado: (2022)

Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide
por: Al Malki, Monzr M., et al.
Publicado: (2022)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

Haploidentical stem cell transplantation with post-transplant cyclophosphamide for osteopetrosis and other nonmalignant diseases
por: Even-Or, Ehud, et al.
Publicado: (2020)

Early Cardiac Toxicity Associated With Post-Transplant Cyclophosphamide in Allogeneic Stem Cell Transplantation
por: Duléry, Rémy, et al.
Publicado: (2021)

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide
por: Bacigalupo, Andrea, et al.
Publicado: (2016)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Primary CNS post-transplant lymphoproliferative disorder following haploidentical HSCT using post-transplant high-dose cyclophosphamide
por: Toyosaki, Masako, et al.
Publicado: (2018)

Fludarabine/Cyclophosphamide Conditioning Regimen in Aplastic Anemia Patients Receiving Matched-Sibling Donor Transplant Is Non-inferior to ATG/Cyclophosphamide: A Single-Center Experience from Pakistan
por: Zaidi, Uzma, et al.
Publicado: (2022)

Immune reconstitution profile after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide
por: Espinoza-Gutarra, Manuel, et al.
Publicado: (2023)

A Review of Cyclophosphamide
por: Fox, B. W.
Publicado: (1975)

Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding
por: Nunes, Natalia S., et al.
Publicado: (2019)

Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan.
por: Millar, J. L., et al.
Publicado: (1975)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Haploidentical Hematopoietic Stem Cell Transplantation Followed by ‘Post-Cyclophosphamide’: The Future of Allogeneic Stem Cell Transplant
por: Cytryn, Samuel, et al.
Publicado: (2020)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post‐transplant cyclophosphamide
por: Jullien, Maxime, et al.
Publicado: (2021)

Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis
por: Gutiérrez-Aguirre, Cesar Homero, et al.
Publicado: (2022)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
por: Crusoe, Edvan De Queiroz, et al.
Publicado: (2020)

Cyclophosphamide for Refractory Acute Cellular Rejection After Lung Transplantation
por: Naik, Chetan, et al.
Publicado: (2018)

Post‐transplant cyclophosphamide as sole GHVD prophylaxis after matched reduced‐intensity conditioning allotransplant
por: Bourgeois, Amandine Le, et al.
Publicado: (2023)

Impacts of post-transplantation cyclophosphamide treatment after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
por: Namdaroglu, Sinem, et al.
Publicado: (2019)

Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation
por: Williams, Louis, et al.
Publicado: (2020)

Post Transplantation Cyclophosphamide Improves Outcome of Autologous Hematopoietic Stem Cell Transplantation in Animal Model of Multiple Sclerosis
por: Kasarełło, Kaja, et al.
Publicado: (2021)

Effect of Hematopoietic Stem Cell Transplantation and Post-Transplantation Cyclophosphamide on the Microglia Phenotype in Rats with Experimental Allergic Encephalomyelitis
por: Kasarełło, Kaja, et al.
Publicado: (2023)

The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation
por: Dybko, Jarosław, et al.
Publicado: (2023)

Thermochemotherapy-induced resistance to cyclophosphamide.
por: Urano, M., et al.
Publicado: (1988)

Distribution and pharmacokinetics of cyclophosphamide in the rat.
por: Talha, M. R., et al.
Publicado: (1980)

Cytotoxicity of cyclophosphamide in the rat incisor.
por: Adatia, A. K.
Publicado: (1975)

Cyclophosphamide-Induced Lung Injury
por: Pugh, Dan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ojjbeo0b0il0behli0g0pmtu0e